Inflammatory Potential of C-Reactive Protein Complexes Compared to Immune Complexes

Romero, Irene; Morris, C; Rodríguez, Mario; Clos, Terry W. Du; Mold, Carolyn

doi:10.1006/clin.1997.4516

Cited by 13 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both CRP and circulating immune complexes are potential activators of the classical complement pathway (21,22,33), and increased levels of both have been described previously in RA. CRP-mediated complement Figure 4.…”

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Evaluation of classical complement pathway activation in rheumatoid arthritis: Measurement of C1q–C4 complexes as novel activation products

Wouters¹,

Voskuyl²,

Molenaar³

et al. 2006

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. Novel activation products that are stable and minimally susceptible to in vitro artefacts have recently been described in the classical complement pathway. The present study assessed circulating levels of these products, i.e., covalent complexes between the recognition molecule of the classical pathway (C1q) and activated C4, in plasma samples from patients with rheumatoid arthritis (RA) to establish the relationship between these levels and the clinical and immunologic parameters in these patients.Methods. C1q-C4 levels were measured in plasma samples from 41 patients with active RA and 43 patients with inactive RA. These levels were related to other complement activation products and to disease activity according to the Disease Activity Score in 28 joints (DAS28), using Spearman's rank correlations.Results. C1q-C4 plasma levels were significantly higher in patients with active RA as compared with patients with RA in clinical remission (median 3.3 arbitrary units [AU], range 0.4-13.4 versus 1.7 AU, range 0.2-5.5; P ‫؍‬ 0.0001), suggesting that activation of the classical complement pathway reflects disease activity. This was supported by a significant correlation between C1q-C4 levels and the DAS28 (r ‫؍‬ 0.398, P ‫؍‬ 0.0002). Levels of other complement activation products, such as activated C4 (C4b/c), were also significantly elevated in patients with active disease compared with patients with inactive disease (P ‫؍‬ 0.03), and were correlated with C1q-C4 levels (r ‫؍‬ 0.329, P ‫؍‬ 0.002). Levels of C1q-C4 complexes were higher in synovial fluid samples than in plasma samples from the 4 patients tested.Conclusion. Systemic complement activation via the classical pathway in patients with RA correlates with disease activity. These results indicate that C1q-C4 complexes may be used as a biomarker for RA.

show abstract

Section: Discussionmentioning

confidence: 83%

“…CRP bound to a ligand can activate complement, and there is evidence that CRP-mediated activation of complement occurs in RA (20). Both immune complexes and ligand-bound CRP activate complement via the classical pathway (18,(21)(22)(23).…”

mentioning

confidence: 99%

Evaluation of classical complement pathway activation in rheumatoid arthritis: Measurement of C1q–C4 complexes as novel activation products

Wouters¹,

Voskuyl²,

Molenaar³

et al. 2006

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…They are related to C-reactive protein (CRP), which is a serum protein that contributes to host defense and is expressed during acute phase inflammatory responses in mammals (9). NPTX2 is homologous to neuronal pentraxin 1 (NPTX1, NP1) and neuronal pentraxin receptor (NPTXR, NPR), both of which have been characterized in nervous system tissues (10).…”

Section: Introductionmentioning

confidence: 99%

Neuronal Pentraxin 2 Supports Clear Cell Renal Cell Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4

et al. 2014

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer, and has the highest propensity to manifest as metastatic disease. Recent characterizations of the genetic signature of ccRCC have revealed several factors correlated with tumor cell migration and invasion; however the specific events driving malignancy are not well defined. Furthermore, there remains a lack of targeted therapies that result in long-term, sustainable response in patients with metastatic disease. We show here that neuronal pentraxin 2 (NPTX2) is over-expressed specifically in ccRCC primary tumors and metastases, and that it contributes to tumor cell viability and promotes cell migration through its interaction with the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunit GluR4. We propose NPTX2 as a novel molecular target for therapy for ccRCC patients diagnosed with or at risk of developing metastatic disease.

show abstract

“…The protein resembles antibody and performs several functions associated with host defence: it promotes agglutination, bacterial capsular swelling and phagocytosis and activates the classical complement pathway through its calcium-dependent binding to phosphocholine (Romero et al, 1998).…”

Section: Discussionmentioning

confidence: 99%

Altered expression of serum protein in ginsenoside Re-treated diabetic rats detected by SELDI-TOF MS

Cho

Yip²,

Chung

et al. 2006

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Inflammatory Potential of C-Reactive Protein Complexes Compared to Immune Complexes

Cited by 13 publications

References 31 publications

Evaluation of classical complement pathway activation in rheumatoid arthritis: Measurement of C1q–C4 complexes as novel activation products

Evaluation of classical complement pathway activation in rheumatoid arthritis: Measurement of C1q–C4 complexes as novel activation products

Neuronal Pentraxin 2 Supports Clear Cell Renal Cell Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4

Altered expression of serum protein in ginsenoside Re-treated diabetic rats detected by SELDI-TOF MS

Contact Info

Product

Resources

About